Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Beyond Sotyktu: Next-Gen TYK2 Drugs Enter Late-Stage Development | Fall Clinical Derm 2025

Summary by Managed Healthcare Executive
Benjamin Lockshin, M.D., from Georgetown University, discusses how oral TYK2 inhibitors that rival biologics’ efficacy have changed the management of patients with psoriasis.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

Managed Healthcare ExecutiveManaged Healthcare Executive

Beyond Sotyktu: Next-Gen TYK2 Drugs Enter Late-Stage Development | Fall Clinical Derm 2025

Benjamin Lockshin, M.D., from Georgetown University, discusses how oral TYK2 inhibitors that rival biologics’ efficacy have changed the management of patients with psoriasis.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Managed Healthcare Executive broke the news in on Sunday, October 26, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Washington DC icon

Washington DC

News
For You
SearchBlindspotLocal